KMTSHealthcare · Medical Instruments & SuppliesThe 8 Wall Street analysts covering Kestra Medical Technologies Ltd. hold a median 12-month price target of $30 — +11.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Kestra Medical Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (60): Sales and profits are climbing, and climbing faster than before.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KMTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +11.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | JP Morgan | Initiates | Overweight | $30 |
| 21 July 2026 | Oppenheimer | Initiates | Perform | — |
| 21 July 2026 | Oppenheimer | Initiates | Perform | — |
| 15 July 2026 | BTIG | Maintains | Buy | $30 → $32 |
| 15 July 2026 | BTIG | Maintains | Buy | — |
| 9 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 7 Apr 2026 | BTIG | Reiterates | Buy | — |
| 25 Mar 2026 | BTIG | Reiterates | Buy | — |
| 18 Mar 2026 | BTIG | Reiterates | Buy | — |
| 15 Dec 2025 | Goldman Sachs | Maintains | Neutral | — |
| 12 Dec 2025 | Piper Sandler | Maintains | Overweight | — |
| 12 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 18 Nov 2025 | BTIG | Initiates | Buy | — |
| 17 July 2025 | Wells Fargo | Maintains | Overweight | — |
| 16 Apr 2025 | Goldman Sachs | Maintains | Neutral | — |
| 31 Mar 2025 | Goldman Sachs | Initiates | Neutral | — |
| 31 Mar 2025 | Piper Sandler | Initiates | Overweight | — |
| 31 Mar 2025 | Stifel | Initiates | Buy | — |
| 31 Mar 2025 | Wells Fargo | Initiates | Overweight | — |
| 31 Mar 2025 | Wolfe Research | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KMTS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 10% of US stocks
Cheaper than 18% of US stocks
Cheaper than 85% of US stocks
Higher than 90% of US stocks
Higher than 79% of US stocks
Higher than 68% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
Higher than 20% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kestra Medical Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kestra Medical Technologies, Ltd. (KMTS) shares surged in the last trading session, with trading volume higher than average. The report notes an 8.1% jump in the share price.
Why it matters — A KMTS watcher would care because the sizable share-price gain on above-average volume signals notable market interest in the stock.
The 8 Wall Street analysts covering Kestra Medical Technologies Ltd. have a median 12-month price target of $30, with estimates ranging from $28 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Kestra Medical Technologies Ltd., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kestra Medical Technologies Ltd. 21 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Kestra Medical Technologies Ltd. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (60 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +11.2% from the last close, and Ticker Nerd's factor model ranks Kestra Medical Technologies Ltd. 21 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kestra Medical Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $32 over the next 12 months.
Kestra Medical Technologies Ltd. returned +58.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Kestra Medical Technologies Inc. is a company specializing in the development and production of innovative medical devices.
The most recent item we track (Zacks Investment Research, 5 Aug 2026): "Strength Seen in Kestra Medical Technologies, Ltd. (KMTS): Can Its 8.1% Jump Turn into More Strength?". Kestra Medical Technologies, Ltd. (KMTS) shares surged in the last trading session, with trading volume higher than average. The report notes an 8.1% jump in the share price.
Kestra Medical Technologies Inc. is a company specializing in the development and production of innovative medical devices. The core function of Kestra is to design wearable medical technologies aimed at improving patient outcomes in critical health areas. Primarily, the company engages in creating devices that focus on cardiac care, providing solutions that monitor, diagnose, and assist in the management of heart conditions. Kestra Medical Technologies addresses significant needs within the healthcare sector, particularly impacting the cardiology field by offering devices that enhance both the quality and efficiency of patient care. As a player in the medical technology industry, Kestra is positioned to influence patient health management trends and contribute to the advancement of medical device technologies. Its products serve as critical tools for healthcare providers aiming to offer cutting-edge care solutions.
CEO Mr. Brian Webster · 443 employees · United States · https://kestramedical.com